chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient reported this on 9/26/2021.  Patient described that after receiving shot he was very tired and sleeping in bed most of the time. He had fever, changes in vision, tired, did not go to restroom and described and stiffness in leg
Patient c/o feeling like heart  is racing and not feeling well. Vitals and Assessment normal.
PT CALLED AT 630 PM COMPLAINING OF HIVES SWOLLEN LIPS AND BOTTOMS OF FEET
It was a respiratory infection. My physician guessed it was RSV. It lasted from 01/15/2023 to about 03/31/2023. I went to the emergency room about a week before I had an appointment with my doctor because my cough was so severe. I was having coughing fits that lasted about 15 minutes or so. I would have symptoms on and off for about two weeks at a time. I had severe cough, difficulty breathing, mild fever at one point. I was given ELLIPTA inhaler with a steroid.
Sore arm, headache, very tired.  No treatment.  Started approximately 18 hrs after vaccination.
On March 8, 2021 @ 1438 1st dose of Moderna vaccine was given to patient in right deltoid. At 1446 patient beckoned for nurse due to feeling nauseous and lightheaded. He was lowered to the floor and assessed. Alert and oriented x3. Denies pain or discomfort. Patient is sweaty and skin pale. States he did not each anything today. Denies having medical problems. Reports having social anxiety and panic attacks. Reports allergies to cashews and nickel (metal). Denies need for EPI pen in the past.  Vitals obtained and WNL. Patient offered water and given protein granola bar to eat. Stayed with patient until symptoms subsided. VS reassessed and continues to be WNL. Patient voices no other needs or concerns. Patient left vaccine site @ 1507 ambulatory, alert, oriented x 3,  and without medical concerns.     1446   VS: O2: 98% RA, R: 18, BP: 132/78, P: 67  1505  VS: O2: 100% RA, R: 18, BP: 122/70, P: 76
Constant very severe headaches and body aches requiring advil every 3-4 hours.  Painful  enough to wake from sleep.  Severe fatigue.
Local reaction at injection site L deltoid, lymphadenopathy developed in axilla with persistent local pain.
he lost his sense of taste; This is a spontaneous report from a contactable consumer (patient) via the Pfizer sponsored program. An 85-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 19Feb2021 (lot number: EL9266; expiry date: unknown) at the age of 85-years-old, as dose 1, single, in the left upper arm for Covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The patient reported that he lost his sense of taste on 20Feb2021. The patient mentioned that he received the 1st dose last Friday, 19Feb2021. On 20Feb2021, after a day or so later, he lost his sense of taste. He mentioned that it was coming back very slowly. He clarified that it was only about 10-15 percent back. He never had a COVID 19 test and showed no other symptoms for COVID-19 so he assumes he was not a victim. Patient would like to know if he should take his second shot. Second injection was scheduled on 12Mar2021. He stated that he can taste spicy things, but he cannot taste things that were not spicy. He can taste salt and pepper, but he cannot taste anything blander than that. Patient's height was between 5ft 9.5 in to 5ft 10 in, while his weight: was 185-190 lbs. Outcome of the event was recovering.  No follow-up attempts are possible. No further information is expected.
Patient died on 3/19/03. Cause of death SIDS. Death occurred two days after immunizations. No problems reported before or after shots.
Rashes along a strip of my torso, on the right side of my body.  Shingles?
You are injecting poison to the people; You are injecting poison to the people; No adverse event; This spontaneous case was reported by a patient and describes the occurrence of SUSPECTED PRODUCT QUALITY ISSUE (You are injecting poison to the people), POOR QUALITY PRODUCT ADMINISTERED (You are injecting poison to the people) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced SUSPECTED PRODUCT QUALITY ISSUE (You are injecting poison to the people), POOR QUALITY PRODUCT ADMINISTERED (You are injecting poison to the people) and NO ADVERSE EVENT (No adverse event). At the time of the report, SUSPECTED PRODUCT QUALITY ISSUE (You are injecting poison to the people), POOR QUALITY PRODUCT ADMINISTERED (You are injecting poison to the people) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            Concomitant medication was not reported. Treatment medication was not reported.
Coughing (no treatment), dizziness (no treatment); extreme sweating during the night at 11:30 pm (no treatment, changed clothes, one time occurrence).
Redness and swelling on (L) arm, warm to touch. Treated with amoxicillin 400mg/5ml.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP) from product quality group. The reporter is the patient.  A 56-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Oct2022 at 18:30 as dose 4 (booster), single (Lot number: 300690345307) at the age of 56 years, in left arm for covid-19 immunization; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history included: "Diabetes" (unspecified if ongoing); "Hypothyroidism" (unspecified if ongoing). The patient's concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Paxlovid started on 27Dec2022 and stopped on 01Jan2023 as treatment for covid-19.
This 11 year old male consumer received 0.5mL of meningococcal polysaccharide vaccine (MCV4) on 10Nov2010 for immunizations at a local health center. The patient's relevant medical history includes: It is unknown if the patient had previous allergic reaction to MCV4. On 13Nov2010 the patient returned to the clinic with possible cellulitis. The patient was triaged by a doctor. Additional laboratory or diagnostic testing was performed. MCV4 was discontinued, the patient was treated with Benadryl, and the cellulitis resolved after that.
The patient received a flu vaccine and approximately 10-15 minutes later was checking out of the clinic when it was noticed that she was developing red welts and tiny blisters across her forehead and cheeks. She was immediately taken back into exam room and undressed to find random welts developing on trunk. MD was immediately paged. Stat order for Benadryl 25mg was given PO. Patient waited in exam room for 20 min and was then re-examined by MD. Patient's hives were starting to resolve and no other symptoms developed. She was discharged in good condition..
The pt experienced mild facial, neck and chest rash. No shortness of breath, airway and lungs clear. Benadryl was given at onset, no other meds. The pt was discharged without symptoms except rash which remained mild. Mother given instructions on signs and symptoms.
A report has been received from a Health Professional concerning a 3 year old, female subject who had been receiving Nasal FLUMIST (INTRANASAL) started on 18-Feb-2014. The patient received expired FLUMIST on 18-Feb-2014. The outcome of the event of INADVERTENTLY GAVE EXPIRED FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.
chest pains; It scared me; This is a spontaneous report from a non-contactable consumer (patient) from a Pfizer Sponsored Program. A female patient of an unspecified age received pneumococcal 13-valent conjugated vaccine (diphtheria crm197 protein) (PREVNAR 13, Solution for injection in pre-filled syringe, lot number and expiry date were not reported), via an unspecified route of administration on an unspecified date as an unknown, single dose for immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced developed chest pains and it scared her. The outcome of the events was unknown.   No follow-up attempts are possible; information about batch/lot number cannot be obtained.
red spot in her arm that keeps getting bigger,arm is all bright red; brain fog; joint pain; muscle pain; Sneezing; Runny nose; arm is hurting, sore; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (red spot in her arm that keeps getting bigger,arm is all bright red), PAIN IN EXTREMITY (arm is hurting, sore), FEELING ABNORMAL (brain fog), SNEEZING (Sneezing) and RHINORRHOEA (Runny nose) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 053C21A and 053E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Joint pain (before getting the vaccine) and Muscle pain (before getting the vaccine). Concurrent medical conditions included Urticaria, Fibromyalgia since 1985, Degenerative disc disease (worse), Bell's palsy (worse), Hay fever and Ascites. Concomitant products included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Allergy, DEXAMETHASONE, NEOMYCIN, POLYMYXIN B (NEOPOLYDEX) from 10-Nov-2021 to an unknown date for Eye disorder, IBUPROFEN for an unknown indication.   On 24-Jul-2021 at 3:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Aug-2021 at 3:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Jul-2021, the patient experienced PAIN IN EXTREMITY (arm is hurting, sore). On 25-Jul-2021, the patient experienced SNEEZING (Sneezing) and RHINORRHOEA (Runny nose). On an unknown date, the patient experienced ERYTHEMA (red spot in her arm that keeps getting bigger,arm is all bright red), FEELING ABNORMAL (brain fog), ARTHRALGIA (joint pain) and MYALGIA (muscle pain). On 26-Jul-2021, PAIN IN EXTREMITY (arm is hurting, sore) had resolved. At the time of the report, ERYTHEMA (red spot in her arm that keeps getting bigger,arm is all bright red), FEELING ABNORMAL (brain fog), SNEEZING (Sneezing), RHINORRHOEA (Runny nose), ARTHRALGIA (joint pain) and MYALGIA (muscle pain) outcome was unknown.            Reported that patient took allergy medication.   This case was linked to MOD-2021-378327 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 08-Nov-2021: Significant follow up received on 08-Nov-2021-Events, medical history and concomitant medications added.
After receiving the first does of the Moderna vaccine the patient was observed for 30min. The patient states she felt heat in her chest and was very shaky. A rash started to appear just before EMS arrived. Pt was given 2 325mg of Tylenol and an icepack was placed on the patients back to reduce heat. We followed up with the patient on 3/20/21 (the day after injection) Patient states she received Benadryl at the ER and is feeling better.
Received immunization 11/19/14 am. Developed left red eye and strange taste in mouth 112/20/14 am. Noted decreased blinking and also drooping of left eye eve 11/20/14; mouth droop on (L) side 11/21/14 eve. Diagnosed with Bell's Palsy on 11/22/14.
IM FLUVIRIN, site itching followed by difficulty breathing (throat constriction) EPI-PEN 0.3 administered and referred to ER for additional eval and treatment.
Headache onset 12 hours after shot. Headache much worse in 2nd day after shot. Woke on the 3rd day with no headache at all. My arm was also very sore at the injection site for several days after the shot. Red rash developed about one week after the shot at injection site (about 3 inches long and 1.5 inches wide. No itching, but my arm felt slightly painful again. The rash is fading and almost gone 24 hours after I first noticed it, but slight pain still present.
Arm is tingling and feeling numb around the injection site. Feels shooting pains in her arm; symptoms began 4 days post injection; patient was advised to contact her PCP
Fever; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant  medication were not provided.  Treatment information were not provided.   Reporter did not allow further contact
This is a spontaneous report received from contactable other HCP (the patient). A 66-year-old female patient received the 3rd (booster) dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# 303135BA), at the age of 65, in left arm, on Sep 26, 2021, single dose, for COVID-19 immunization. Vaccination history included the 2nd dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# EL3248), in left arm, on Feb 5, 2021, and the 1st dose of Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), in left arm, on Jan 14, 2021; both single dose, for COVID-19 immunization. No medical history. The patient's concomitant medications not reported. The patient experienced vaccination failure (medically significant) and COVID-19/suspected COVID-19 (medically significant), onset 2022, with outcome of unknown. Therapeutic measures were taken as a result of suspected COVID-19. No follow-up attempts needed. No further information expected.
Patient developed a fever around midnight of 8/21. At 4:30 AM his wife found him having a seizure, 3 in a row, without gaining consciousness in between. He was transferred via ambulance to Hospital. He was then transferred on 8/21 to another Hospital. He was treated with sedation, then started on KEPPRA and VIMPAT. It was 10 days before he regained consciousness, and he was in the neurological ICU the whole time. He was subsequently transferred to the stroke floor, then discharged to a rehabilitation facility on 9/19/18.
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. No information about the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On two separate unknown dates, the patient received a total of two doses of ZOSTAVAX (dose, route of administration, lot # and expiration date were not reported). No adverse symptoms were reported. Additional information has been requested.
Generalized wheals shortly after administration of vaccine. Irritability. Treatment Benadryl IM, SoluMedrol IM 01/18/07-records received and reviewed, generalized wheals, treated with Benadryl and SoluMedrol IM
Per patient: arm got hot, swollen at injection site, and sore. Large bump after injection. Arm very sore and weak and it was very painful to even wash her hands. Used a heating pad and it felt better. Cold compresses made it feel worse. Went to doc and doctor said that it was an allergic reaction. She is now taking OTC CLARITIN 10mg once a day (she thinks it is CLARITIN). It is getting better, but slowly.
10/14/2006 pt presented with lateral thigh edema, erythema, cellulitis at site treated for cellulitis with Augmentin.
"Genital warts that have been present for 5 years and no mouth ulcers at all since 1st shot and mouth ulcers are pretty common for me."; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK9231), via an unspecified route of administration in the left arm on 20Jan2021 at 15:00(at the age of 33-year-old), as a single dose for COVID-19 immunisation and also received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL8982), via an unspecified route of administration in the left arm on an unknown date as a single dose for COVID-19 immunisation. Medical history included genital wart present for 5 years and mouth ulcers were pretty common. The patient did not have a history of allergies to any food or medications or other products. The patient did not receive any other medications within two weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 24May2021, the patient reported genital warts that have been present for 5 years and no change over the past 5 years have completely disappeared 3 months after 2nd shot with the exception of 1 small spot that not resembles a pimple (over10 warts to begin with). Also their was no mouth ulcers at all since1st shot and mouth ulcers are pretty common for her.  The lot number for the vaccine (PFIZER-BIONTECH COVID-19 mRNA VACCINE) was not provided and will be requested during follow up.
Red rash that slowly covered her whole body. Not raised or itchy, just small red spots everywhere.
Vomiting, diarrhea and fever 38.6 C 1 day after immunization - BM's X 6.
This non-serious spontaneous case, initially received from other non-health professional on 02-Nov-2018, concerns a 66-year-old, elderly patient of an unspecified gender. It was reported that, the FLUAD (TIV) vaccine underwent temperature excursion for the first time. The vaccine was out for around 48 hours and it reached 11.6 degree Celsius. On 17-Oct-2018, the patient was administered FLUAD (TIV) [route of administration: intramuscular, anatomical location: left deltoid, batch number: 250802, expiry date: 30-Jun-2019 and dose: not reported] which underwent temperature excursion. The reported batch number (250802), dose not match FLUCELVAX batch numbers, however, the batch number was mapped to FLUAD (TIV). Hence, the suspect vaccine was coded as FLUAD (TIV). At the time of this report, no adverse event was reported. This case 201805455 was crossed linked to original cases 201804863 due to same reporter.
two days following flu like aches and pains. three days after experienced shortness of breath on going. one week after sky rocketing increase in blood pressure. 200/125 ongoing
Inappropriate schedule of vaccine administration; This case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in Jun 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 22-Jun-2022 Reporter's comments: The patient had not received dose two at the moment of the report. The reporter gave consent to follow up. Additional Supportive Information: Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination.
Episode of syncope with second HPV vaccine today. It is unknown if the patient had and episode with first dose. Patient is alert, responsive 2 minutes after episode.  BP 108/78 with pulse rate of 68 bpm.  Patient stayed in office for 45 minutes after episode with no further signs or symptoms of syncope. Mother picked up patient at 12:15 pm to drive pt home. Patient advised not to seek third dose of HPV.
Vaccinated with 1st dose of varicella virus vax/live on 7/6/99 and 2nd dose on 9/28/88. During wk. of 10/4 the pt. had dizziness, gas in her stomach, burping & periodic uncontrollable shaking. She was taken to ER on 10/9, all test were neg.
pt recvd vax 14DEC95 @ 1400; @1700 began experiencing aches, lethargy, & lightheadedness;by the next day, had improved;
Patient came in with echinosis and petechia - Rash on both lower extremities. -HSP. 2ry to vaccine.
My left arm received the shot.  It has been sore since I received it.  Now the soreness is in the back of my underarm and at the top of my shoulder blade.  I can lift my arm up not even half way since I took the shot.  If I try to lift my arm up any further it hurts really bad.
administrating only the diluent portion / administration of the diluent alone; administrating only the diluent portion / administration of the diluent alone; This case was reported by a other health professional via sales rep and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In July 2021, the patient received Shingrix. In July 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The account manager from GlaxoSmithKline called to report that he was informed by a third person, that an health care professional was administrating only the diluent portion of the Shingrix vaccine to the patient, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter stated that, the patient received Shingrix vaccine through 26th July 2021 to 29th July 2021. The reporter gave the health care professional contact information but did not specify if the health care professional agreed to be contacted for follow up or not. There was no further information regarding the date of the administration, nor lot number or expiration date of the vaccine. No further information was given to the account manager or to the agent. This case was 1 of 9 linked cases, reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021165607:Same reporter US-GLAXOSMITHKLINE-US2021AMR167670:Same reporter US-GLAXOSMITHKLINE-US2021AMR167671:Same reporter US-GLAXOSMITHKLINE-US2021AMR167675:Same reporter US-GLAXOSMITHKLINE-US2021AMR167677:Same reporter US-GLAXOSMITHKLINE-US2021AMR167676:Same reporter US-GLAXOSMITHKLINE-US2021AMR167673:Same reporter US-GLAXOSMITHKLINE-US2021AMR167674:Same reporter